Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-Included Resected Hepatocellular Carcinoma Patients

2018 ◽  
Author(s):  
Gui-Qi Zhu ◽  
Yi Yang ◽  
Er-Bao Chen ◽  
Biao Wang ◽  
Kun Xiao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Gene Signature ◽  
Development And Validation

scholarly journals Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma

Genomics ◽  
2020 ◽  
Vol 112 (4) ◽  
pp. 2763-2771 ◽  
Author(s):  
Bo-Han Zhang ◽  
Jian Yang ◽  
Li Jiang ◽  
Tao Lyu ◽  
Ling-Xiang Kong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Gene Signature ◽  
Prognosis Prediction ◽  
Development And Validation

scholarly journals A Bioinformatics Analysis Identifies the Telomerase Inhibitor MST-312 for Treating High-STMN1-Expressing Hepatocellular Carcinoma

2021 ◽  
Vol 11 (5) ◽  
pp. 332
Author(s):  
Szu-Jen Wang ◽  
Pei-Ming Yang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Kinase Inhibitors ◽  
Cancer Genomics ◽  
Gene Signature ◽  
Migration And Invasion ◽  
Advanced Hcc ◽  
Telomerase Inhibitor ◽  
Cell Cycle Related Gene ◽  
Hcc Cells

Hepatocellular carcinoma (HCC) is a relatively chemo-resistant tumor. Several multi-kinase inhibitors have been approved for treating advanced HCC. However, most HCC patients are highly refractory to these drugs. Therefore, the development of more effective therapies for advanced HCC patients is urgently needed. Stathmin 1 (STMN1) is an oncoprotein that destabilizes microtubules and promotes cancer cell migration and invasion. In this study, cancer genomics data mining identified STMN1 as a prognosis biomarker and a therapeutic target for HCC. Co-expressed gene analysis indicated that STMN1 expression was positively associated with cell-cycle-related gene expression. Chemical sensitivity profiling of HCC cell lines suggested that High-STMN1-expressing HCC cells were the most sensitive to MST-312 (a telomerase inhibitor). Drug–gene connectivity mapping supported that MST-312 reversed the STMN1-co-expressed gene signature (especially BUB1B, MCM2/5/6, and TTK genes). In vitro experiments validated that MST-312 inhibited HCC cell viability and related protein expression (STMN1, BUB1B, and MCM5). In addition, overexpression of STMN1 enhanced the anticancer activity of MST-312 in HCC cells. Therefore, MST-312 can be used for treating STMN1-high expression HCC.

Sign in / Sign up

Export Citation Format

Share Document